Complementation of NADPH oxidase in p67-phox-deficient CGD patients p67-phox/p40-phox interaction.
Chronic granulomatous disease (CGD) is due to a functional defect of the O2- generating NADPH oxidase of phagocytes. Epstein-Barr-virus-immortalized B lymphocytes express all the constituents of oxidase with activity 100 times less than that of neutrophils. As in neutrophils, oxidase activity of Epstein-Barr-virus-immortalized B lymphocytes was shown to be defective in the different forms of CGD; these cells were used as a model for the complementation studies of two p67-phox-deficient CGD patients. Reconstitution of oxidase activity was performed in vitro by using a heterologous cell-free assay consisting of membrane-suspended or solubilized and purified cytochrome b558 that was associated with cytosol or with the isolated cytosolic-activating factors (p67-phox, p47-phox, p40-phox) from healthy or CGD patients. In p67-phox-deficient CGD patients, two cytosolic factors are deficient or missing: p67-phox and p40-phox. Not more than 20% of oxidase activity was recovered by complementing the cytosol of p67-phox-deficient patients with recombinant p67-phox. On the contrary, a complete restoration of oxidase activity was observed when, instead of cytosol, the cytosolic factors were added in the cell-free assay after isolation in combination with cytochrome b558 purified from neutrophil membrane. Moreover, the simultaneous addition of recombinant p67-phox and recombinant p40-phox reversed the previous complementation in a p40-phox dose-dependent process. These results suggest that in the reconstitution of oxidase activity, p67-phox is the limiting factor; the efficiency of complementation depends on the membrane tissue and the cytosolic environment. In vitro, the transition from the resting to the activated state of oxidase, which results from assembling, requires the dissociation of p40-phox from p67-phox for efficient oxidase activity. In the process, p40-phox could function as a negative regulatory factor and stabilize the resting state.
Vergnaud
S
S
GREPI, Laboratoire d'Enzymologie, CHU, Grenoble, France; INSERM U. 479, CHU, Bichat, Paris, France.
Paclet
M H
MH
El Benna
J
J
Pocidalo
M A
MA
Morel
F
F
D001402:B-Lymphocytes / Q000166:cytology / Q000201:enzymology; D015153:Blotting, Western; D002461:Cell Line, Transformed; D002462:Cell Membrane / Q000201:enzymology; D003573:Cytochrome b Group / Q000302:isolation & purification / Q000378:metabolism; D003600:Cytosol / Q000737:chemistry / Q000201:enzymology; D004789:Enzyme Activation; D004795:Enzyme Stability; D005816:Genetic Complementation Test; D006105:Granulomatous Disease, Chronic / Q000201:enzymology* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D006801:Humans; D019255:NADPH Oxidases / Q000037:antagonists & inhibitors / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D009504:Neutrophils / Q000166:cytology / Q000201:enzymology; D010750:Phosphoproteins / Q000172:deficiency* / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism*; D011485:Protein Binding; D011993:Recombinant Fusion Proteins / Q000302:isolation & purification / Q000378:metabolism; D012995:Solubility
D003573:Cytochrome b Group; D010750:Phosphoproteins; D011993:Recombinant Fusion Proteins; C085072:neutrophil cytosol factor 40K; C079789:neutrophil cytosol factor 67K; C036888:cytochrome b558; D019255:NADPH Oxidases; C060505:neutrophil cytosolic factor 1